RESUMO
Objective To investigate effect of compound mylabris capsules combined with neoadjuvant on efficacy and expression of Ki67,ER,PR in patients with HER2-negative breast carcinoma.Methods Eighty-one HER2 negative-breast cancer patients from the hospital were randomly divided into treatment group(41cases) and control group(40 cases) by random number table method.Control group was treated with three weeks of neoadjuvant chemotherapy,firstly given with cyclophosphamide(CTX)600 mg/m2 +adriamycin amycin(Ad)60 mg/m2,and then next course with docetaxel(DOC) 100 mg/m2, intravenous drip for 1 h,one period per three weeks,one times per week,and for 6 periods.Patients in treatment group were additionally given with compound mylabris capsules from one day before chemotherapy,three particles per time,two times per day,seven times per period,and for another one week after chemotherapy.Score of traditional Chinese medicine(TCM) symptoms,clinical efficacy,and levels of hemorheology indexs were compared.Serum levels of Ki67,ER,and PR were detected between both groups.Results Total efficacy of treatment group was recently 56.10%,which was superior to control group 30.00%(P<0.05).AT the ending of chemotherapy and 1 weeks after chemotherapy,TCM score, plasma viscosity,and high, middle and low shear of whole blood were obviously lower than control group(P<0.05).Serum level of Ki67 in treatment group was lower, while ER and PR were higher than control group at the ending of chemotherapy and 1 weeks after chemotherapy with statistically significant difference ( P<0.05).Conclusion Compound mylabris capsules combined with neoadjuvant chemotherapy in treating breast carcinoma with HER2 negative can decrease TCM symptoms, improve blood viscosity and clinical efficacy,and inhibit expression of Ki67 and up-regualte ER and PR levels.
RESUMO
To investigate the relationship between the prognosis and the HER-2 expression and its significance as a prognosis predictor in patients with breast cancer. In 185 samples of breast cancer the expression of HER-2 was immunchistochemically deternined and the survival time of the patients was respectivaly affirmed. 120 patients (64.9%) with complete followed-up data were indudal, of whom 28 patients died (15%). The records of other 65 patients (35.1%) were not available for this study. It was showed that the positive rate for HER2 was 37.3%. There was significant difference between the survival curves in patients exhibiting different grades of HER2 expression (P